Tasly Pharmaceutical Group Co., Ltd (600535.SS) released a profit for its full year that Increased, from the same period last year
The company's bottom line totaled RMB1.104 billion, or RMB0.74 per share. This compares with RMB955.586 million, or RMB0.64 per share, last year.
The company's revenue for the period fell 3.1% to RMB8.236 billion from RMB8.498 billion last year.
Tasly Pharmaceutical Group Co., Ltd earnings at a glance (GAAP) :
-Earnings: RMB1.104 Bln. vs. RMB955.586 Mln. last year.-EPS: RMB0.74 vs. RMB0.64 last year.-Revenue: RMB8.236 Bln vs. RMB8.498 Bln last year.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.